All three data tools (get_stock_data, get_verified_market_snapshot, get_indicators) are disabled in this deployment and returned NO_DATA_AVAILABLE for BAX. Per protocol I attempted the full chain — price CSV first, then indicator computation, then the verified snapshot as source of truth — and all three failed. This means no OHLCV series, no computed indicator values, no verified price levels, and no chart-based observations are available in provided documents. Everything below is therefore built strictly from the four permitted source documents (FACTS / FILING / EIGHTK / THIRTEENF), with all market-data gaps explicitly flagged rather than filled.

BAX (Baxter International Inc, NYSE) — Analysis & Indicator Selection Report

Date of analysis: 2026-09-18 · Sector: Health Care · Industry: Health Care Equipment

1. Tool & Data Availability Disclosure (read first)

Consequence: Any statement about exact prices, OHLCV, support/resistance levels, percentage moves, gaps, trend lines, or indicator readings (other than the MFI figure quoted in FACTS) is not available in provided documents and is deliberately excluded from this report. The discrepancy to flag is the absence itself: the verified snapshot could not be retrieved, so no reconciliation between tool outputs is possible — I will not invent one.

2. What the Source Documents Establish

2.1 Quantitative signal context (FACTS — QuantOrb money-flow engine, 2026-09-17 US session)

• MFI reading: 15.99 — by conventional money-flow interpretation, a reading below 20 sits in oversold territory. Critically, MFI is volume-weighted, so this is not just price weakness; it reflects money flow pressure as of the 2026-09-17 US session.
• Signal: BUY, signal strength 0.7468 — a strong screen output. The document itself is explicit: "The signal is a quantitative screen output, not a recommendation." I treat it identically: a conditional input, not a verdict.
• Tactical interpretation: deep money-flow oversold readings can mark either (a) a capitulation/mean-reversion zone, or (b) the early-middle stage of a persistent downtrend where MFI "walks" along the floor. The distinguishing evidence — RSI behavior, band dynamics, MACD histogram shape — is not available in provided documents.

2.2 Fundamental narrative (EIGHTK — Q2 2026 press release, 2026-07-30)

• Sales $2.96B, +5% reported and +5% organic, growth across all segments and divisions — a broad-based quarter, not a one-segment story.
• GAAP diluted EPS $0.26 vs adjusted diluted EPS $0.56 — a $0.30 gap between GAAP and adjusted results. This spread is materially wide and, per the release, includes "an additional benefit from a tariff refund that was not previously contemplated in our guidance." Earnings-quality nuance: part of the beat is a one-time refund, so the Q2 adjusted print likely overstates the clean run-rate. This matters for anyone sizing an oversold-reversal trade — the "beat" was real, but partially non-recurring.
• Company raised full-year 2026 outlook — positive guidance momentum, the strongest fundamental datapoint in the file.
• CEO Andrew Hider's language is the tell for regime: "further stabilizing the business, strengthening the balance sheet and driving a culture of continuous improvement." That is a turnaround/rebuild vocabulary, not a growth-at-peak vocabulary. A company still "strengthening" its balance sheet is one where drawdowns can be sharp and volatile — a direct argument for volatility-adjusted risk management (see ATR below).

2.3 Cash deployment & operational history (FILING — 10-K, filed 2026-02-12)

• Capex $513M in 2025, explicitly aimed at production efficiency, quality systems, and manufacturing capability for growth — capacity is being built, i.e., management is investing through the rebuild.
• Dividends paid in 2025: $348M — the dividend was maintained through the rebuild year. Note: dividend figures for 2026 are not available in provided documents; the $348M is a 2025 fact only.
• Hurricane Helene / North Cove (Marion, N.C.): damaged September 2024, fully operational by end of Q1 2025. Practical implication for 2026: the facility-recovery drag is behind the company; 2026 comparisons do not carry that disruption. (Any claim about insurance recoveries, remediation costs, or their financial size is not available in provided documents.)
• The filing frames the business narrative around "stockholder value creation… consistent with our previously stated commitment to achieve our net leverage targets" — corroborating the EIGHTK's balance-sheet theme: deleveraging is an explicit, standing objective.

2.4 Institutional positioning (THIRTEENF — as of 2026-03-31, statutory lag up to 45 days; ~5.5 months stale as of today, 2026-09-18)

Synthesis: the tape of holders is mixed but value-tilted — two deep-value-style filers adding aggressively (one nearly tripling), one large holder trimming ~8%, one small holder cutting ~24%. That pattern (value buyers accumulating into weakness while some holders rotate out) is consistent with — though not proof of — the oversold/contrarian setup implied by MFI 15.99. Caveats: this is a top-holder snapshot of only 5 filer rows, not exhaustive 13F coverage; it is a periodic regulatory disclosure, not real-time positioning; and it predates the Q2 beat and guidance raise by three months. More recent positioning is not available in provided documents.

3. Indicator Selection — 8 Chosen Indicators and Why

The market condition to design for: a deeply oversold, volume-weighted money-flow condition (MFI 15.99) with a strong BUY screen signal (0.7468), layered on a company in a documented turnaround (balance-sheet strengthening, raised guidance, one-time refund inflating the last beat) and mixed institutional flow. The right toolkit therefore must answer four questions: (1) Is this oversold bounce or downtrend continuation? (2) Is momentum turning? (3) Is price statistically stretched? (4) How do I size and stop the trade in a potentially volatile rebuild story? The eight picks below cover those four questions with minimal overlap.

Moving Averages (trend regime + timing)

1. close_200_sma — the strategic regime filter. This is the single most important inclusion: a BUY signal at MFI 15.99 means entirely different things above the 200 SMA (dip in an uptrend) than below it (bear-market bounce / potential death-cross regime). Given the turnaround narrative, I would expect BAX to be interacting with its long-term average from below — but that is a hypothesis, and the actual price-vs-200-SMA state is not available in provided documents. It must be confirmed before any entry.
2. close_50_sma — the medium-term battleground. For a rebuild story, the reclaim or rejection of the 50 SMA is the classic "recovery is real" checkpoint, and it serves as the dynamic reference for where a bounce could stall. Lags price, which is acceptable here — we are filtering a screen signal, not scalping.
3. close_10_ema — the timing trigger. Once the oversold condition is in place, the 10 EMA is the earliest responsive gauge of whether buyers have actually taken control (price reclaiming the 10 EMA and the 10 EMA turning up over the 50 SMA is the minimal momentum confirmation). Prone to noise — which is exactly why it is only used in combination with #1 and #2, never alone.

MACD Family (momentum turn + divergence detection)

1. macd — the momentum-trend crossover engine. In oversold regimes the highest-quality signals are crossovers and especially bullish divergences (price making marginal lows while MACD lifts). A divergence would materially raise confidence that the MFI 15.99 reading is capitulation rather than trend continuation. Not available here — must be verified.
2. macdh — the early-warning layer. The histogram often contracts toward zero before the MACD line crosses its signal, giving the earliest read on downside momentum deceleration. I deliberately select the histogram instead of macds to avoid redundancy: the histogram is, by construction, the gap between the MACD line and the signal line, so it carries the signal-line information in a more sensitive form. macds would be a third look at the same arithmetic.

Momentum (oversold cross-check)

1. rsi — the non-volume momentum counterpart to MFI. This is the key redundancy-management decision in the whole selection: MFI (from FACTS) is volume-weighted; RSI is price-only. They are complementary, not duplicative — the single most informative confirmation for this setup is whether RSI is also sub-30 / hooking upward while MFI sits at 15.99. Agreement = strong oversold confluence; disagreement (e.g., RSI already rebounding to 45 while MFI stays depressed) is itself a tradable insight about where money flow lags price. (I do not select stochrsi or any second momentum oscillator — redundant with RSI by design.)

Volatility / Bands (stretch + risk)

1. boll_lb — the statistical-stretch check. A MFI of 15.99 should, in a coherent tape, coincide with price pressing or piercing the lower Bollinger band. Two uses: (a) entry confluence — a lower-band tag plus sub-20 MFI is the classic mean-reversion cluster; (b) regime warning — if price "walks the lower band" for many consecutive sessions, the reading is trend continuation, not reversal, and the BUY screen should be overridden. I do not take boll (middle) because it is a 20 SMA and its trend role is already covered by the 50/200 SMA pair, and not boll_ub because the setup is an oversold-long, not a breakout-short.
2. atr — the risk-management backbone, arguably the most important practical pick. The EIGHTK language ("strengthening the balance sheet") plus a turnaround microstructure plus tariff-refund earnings noise implies elevated and regime-dependent volatility. ATR converts that into concrete mechanics: stop distances and position size expressed as multiples of current ATR (e.g., a stop placed 1.5–2.0× ATR below entry, and size scaled inversely to ATR so that dollar risk is constant). Because ATR is reactive, it is used only inside a broader plan — which is exactly what the surrounding seven indicators provide.

Deliberately excluded: macds (redundant with macd + macdh), boll and boll_ub (covered by the 50/200 SMA and the oversold-long context respectively), vwma (its job — integrating volume into the trend read — is already performed by the MFI reading at the heart of this setup; keeping it would double-count volume information). If a substitution were ever needed, vwma is the first alternate, since volume-confirmed price recovery would corroborate the money-flow signal directly.

Status note: all eight indicator values are not available in provided documents — the selection above is the correct plan, but none of the levels, crossovers, or divergence patterns can be confirmed in this deployment.

4. Actionable Trading Framework (conditional — execution gated on data that is currently unavailable)

Setup thesis (documented): Q2-2026 delivered broad-based 5% organic growth and a raised FY2026 outlook (EIGHTK), the Helene/North Cove operational drag ended by Q1 2025 (FILING), and deep-value filers were adding as of the last 13F snapshot (THIRTEENF) — while the money-flow engine flags a strong oversold BUY condition (FACTS). Against that: an explicit ongoing balance-sheet rebuild, a wide GAAP/adjusted EPS gap inflated by a non-contemplated tariff refund, and the largest tracked 13F holder trimming.

Entry logic — demand confluence, never the screen signal alone: 1. ✅ Base condition (already met, per FACTS): MFI 15.99 with BUY strength 0.7468 as of 2026-09-17. 2. ⬜ RSI cross-check: sub-30 and turning up (agreement with MFI), or a clear bullish RSI divergence. 3. ⬜ Bollinger context: price tagging/piercing boll_lb — but verify it is a first stretch, not a multi-session band-walk. 4. ⬜ Momentum: macdh contracting toward zero from deeply negative, ideally with a bullish macd divergence. 5. ⬜ Regime gate: know exactly where price sits vs close_200_sma and close_50_sma. Below both → treat as counter-trend, half-size or stand aside; a confirmed 10 EMA reclaim and 50 SMA cross is the upgrade trigger.

Risk management (mechanics, not fabricated levels): - Size the position so that a stop at 1.5–2.0× ATR below entry equals a fixed, pre-committed dollar risk. Because ATR is unavailable, no absolute stop price can be stated here — compute it when data access is restored. - Re-check sizing against event risk: the next earnings report date is not available in provided documents; do not carry maximum size into an unknown print for a company that just surprised on a one-time refund. - Invalidation: persistent lower-band rides with macdh expanding negatively, or a decisive break below the structural reference the 200 SMA provides — in that world, the MFI-based BUY screen is early, and "early" and "wrong" are different words for the same loss.

What would strengthen the thesis (monitoring list): - Confirmation that the FY2026 guidance raise is not solely tariff-refund-dependent (the release does not decompose the raise — decomposition is not available in provided documents). - The next 13F cycle to see whether Greenhaven/Front Street adds continued after the Q2 beat (current file is frozen at 2026-03-31 and is ~5.5 months stale). - Any disclosure on dividend policy for 2026 (2025's $348M is the only dividend fact on file). - Continued progress language on net-leverage targets from the 10-K commitment.

Explicit non-claims: I make no claims about current price, daily moves, gaps, 52-week ranges, support/resistance bounces, historical validation of any pattern, or any indicator numeric value — all of that is not available in provided documents in this deployment. Per my role, I report what the tools support (here: nothing) — another agent with live data access decides the trade.

5. Key Points Summary Table

Bottom line: the documentary record supports a coherent contrarian-long hypothesis — strong oversold money-flow signal, raised guidance, operational drag cleared, value filers accumulating — but every technical trigger (SMA regime, RSI, MACD, bands, ATR sizing) and every price level is unverifiable in this deployment. Treat MFI 15.99 / BUY 0.7468 as a condition to be confirmed, not a trade to be taken.

Overall Sentiment: Mildly Bullish (Score: 6.2/10) Confidence: Low

BAX Sentiment Report — 2026-09-11 to 2026-09-18

Data availability caveat (important)

All three social/news sentiment sources are unavailable in this deployment: Yahoo Finance headlines, StockTwits messages, and Reddit posts all returned placeholder/unavailable markers. There is therefore no retail or news sentiment signal for this window — "not available in provided documents". The read below is built entirely on the quantitative money-flow snapshot, SEC filings/press release, and institutional 13F positioning.

Source-by-source breakdown

1. QuantOrb money-flow engine (2026-09-17 session)

• MFI reading of 15.99 — very low on the 0–100 money-flow index, indicating the stock has been under sustained selling/oversold conditions.
• Engine signal: BUY, signal strength 0.7468 — a moderately strong quantitative screen output (explicitly not a recommendation). A low MFI paired with a BUY signal is a classic mean-reversion/oversold configuration.
• Direction: bullish-tilted (contrarian/technical).

2. Q2 2026 earnings 8-K (2026-07-30) — most recent fundamental event

• Sales of $2.96B, +5% reported and organic, growth across all segments and divisions.
• GAAP diluted EPS $0.26; adjusted diluted EPS $0.56.
• Company raised full-year 2026 outlook. CEO Andrew Hider cited results "exceeded expectations on both the top and bottom lines," including an un-forecast tariff refund benefit (a one-time quality-of-earnings caveat), and emphasized stabilizing the business and "strengthening the balance sheet" — language that implies balance-sheet work is still in progress.
• Direction: constructively bullish fundamentals, with a one-time gain and a still-unfolding turnaround as caveats.

3. 10-K (filed 2026-02-12)

• Capex of $513M in 2025 focused on efficiency, quality systems, and capacity expansion; dividends paid of $348M in 2025 — continued capital return despite leverage-reduction framing.
• Hurricane Helene North Cove disruption resolved: facility fully operational by end of Q1 2025 — a historical risk now retired.
• Direction: neutral-to-slightly-positive; dividend maintained, leverage commitment stated.

4. 13F institutional positioning (as of 2026-03-31; up to 45-day lag)

Divergent flows among tracked top holders: - Pzena Investment Management: -7.9% (trimmed ~5.5M shares, still the dominant holder at ~64.5M) — the largest holder reducing is a mild negative. - Greenhaven Associates: +33.8% (~3.6M shares added) — deep-value buyer adding aggressively. - Front Street Capital: +176.6% — small position but a sharp add. - Pale Fire Capital: -23.7% — small holder trimming. - Net read: mixed institutional positioning, with value-oriented buyers offsetting reductions by the largest holder.

Cross-source divergences and alignments

• Alignment: the oversold MFI (technical) plus the raised FY2026 guidance (fundamental) both point toward a beaten-down stock with improving fundamentals — a coherent mild-bullish setup.
• Divergence: within institutional flows, the largest holder (Pzena) cut while value buyers (Greenhaven, Front Street) added — no consensus among tracked filers.
• No social/news sources available, so no retail-vs-institutional divergence can be assessed.

Dominant narrative themes

1. Turnaround/stabilization under new leadership (CEO Hider, GPS program) — balance-sheet strengthening and continuous improvement.
2. Oversold technical condition (MFI ~16) against improving operating results (+5% organic growth, raised guidance).
3. Capital discipline: continued dividends ($348M in 2025) alongside $513M capex and net-leverage targets.

Catalysts and risks

• Catalysts: sustained organic growth into Q3 2026 results; continued execution under GPS; potential mean-reversion from oversold conditions.
• Risks: the Q2 beat included a one-off tariff refund not contemplated in guidance (quality-of-beat caveat); management's own "strengthening the balance sheet" language signals leverage work remains incomplete; Pzena's reduction suggests some large-holder caution; 13F data is stale (2026-03-31). Q3/next earnings, guidance revisions, and macro/tariff developments are catalysts not covered in the provided documents.

Summary table

Bottom line

With all social/news sources silent, the sentiment read rests on an oversold technical setup (MFI 15.99 with a BUY screen signal) and constructive Q2 2026 fundamentals (raised guidance, broad-based 5% organic growth), partially offset by a one-time earnings benefit, incomplete balance-sheet repair, and mixed institutional flows. That combination supports a Mildly Bullish band at score ~6.2 with low confidence — the absence of any news or retail data means a significant sentiment driver could be missing from this window. This is signal to weigh alongside fundamentals and technicals, not a price call.

BAX (Baxter International Inc, NYSE: BAX) — News & Trend Research Report

Analysis date: 2026-09-18 | Prepared for trading workflow

0. Tool & Data Availability Notice

All four external data tools (get_news, get_global_news, get_macro_indicators, get_prediction_markets) were called for the window 2026-09-11 → 2026-09-18 and returned NO_DATA_AVAILABLE — external market data access is disabled in this deployment. Accordingly, this report is built exclusively from the four source documents provided (QuantOrb money-flow snapshot, SEC 10-K excerpt, SEC 8-K Q2 2026 press release, SEC 13F-HR snapshot). Any item not covered by these documents is explicitly flagged as "not available in provided documents." No prices, macro prints, or events have been fabricated.

1. Company & Quantitative Signal Snapshot

Interpretation: The Money Flow Index at 15.99 sits in the teens — a zone conventionally read as oversold-type selling exhaustion (classic MFI thresholds put readings below ~20 in oversold territory). Combined with a BUY signal of meaningful strength (0.7468), the quant screen is flagging that recent-session money flow pressure on BAX may be overextended to the downside. Important caveats: (1) this is a quantitative screen output, not a recommendation; (2) no current price, volume, or chart data is available in provided documents, so entry levels cannot be specified from evidence on hand.

2. Fundamentals — Q2 2026 Results (8-K Item 2.02, filed 2026-07-30)

The most recent hard fundamental datapoint for BAX is its second-quarter 2026 press release (July 30, 2026). Key figures:

• Sales: $2.96 billion, +5% on both a reported and organic basis — with growth in all segments and divisions.
• U.S. GAAP diluted EPS: $0.26; adjusted diluted EPS: $0.56.
• Company raised its full-year 2026 financial outlook.
• CEO Andrew Hider attributed the top- and bottom-line beat to "both operating performance and an additional benefit from a tariff refund that was not previously contemplated in our guidance."
• Strategic framing: the Baxter Growth and Performance System (GPS) program — focused on "further stabilizing the business, strengthening the balance sheet and driving a culture of continuous improvement."

Trading-relevant nuances: 1. Quality of beat is mixed. Part of the upside came from a one-off tariff refund outside original guidance. Traders should treat the raise as partly non-operational in origin and watch whether the next print shows the underlying organic momentum standing on its own. The broad-based nature of growth (all segments and divisions) is the supportive element. 2. Tariff exposure is confirmed as a live cost theme. The existence of a tariff refund implies tariffs have been a cost headwind for BAX — a recurring margin consideration for a global medtech manufacturer. 3. Comparability friction: Organic growth excludes the Kidney Care Manufacturing and Supply agreement (Kidney Care MSA) impact not reflected in reportable segments, plus M&A/divestiture effects, at constant currency. Reported-vs-organic gaps should be expected in future quarters.

(Note: the source is explicitly a press release, not an earnings call transcript — no management Q&A color is available in provided documents. Full guidance tables, segment detail, and cash-flow statements are also not available in provided documents.)

3. Structural Backdrop — 10-K (filed 2026-02-12)

• Capital discipline: 2025 capital expenditures totaled $513 million, targeted at production efficiency, quality systems, and manufacturing capability for growth.
• Shareholder returns: $348 million in cash dividends paid during 2025 — an income component that has continued through the restructuring phase.
• Leverage commitment: The 10-K frames capital allocation as consistent with the company's "previously stated commitment to achieve our net leverage targets" — corroborating the CEO's balance-sheet-strengthening priority in the Q2 release.
• Supply-chain risk precedent — Hurricane Helene: The September 2024 flood event damaged assets at the North Cove facility (Marion, N.C.); the facility was fully operational by the end of Q1 2025. This is a resolved event, but it demonstrates the operational/deconsolidation risk profile of Baxter's manufacturing network — relevant context for how the market may price any future manufacturing disruption.

(Detailed MD&A financials are not available in provided documents — the excerpt covers only the opening of Item 7.)

4. Institutional Positioning — 13F-HR Snapshot (positions as of 2026-03-31)

Staleness warning: These are quarter-end positions from 2026-03-31, subject to a statutory reporting lag of up to 45 days — nearly six months old as of this analysis date. Treat as background positioning, not current flows.

Read-through: The mix is divided. The largest tracked holder (Pzena, a deep-value shop) trimmed modestly (−7.9%), and Pale Fire cut harder (−23.7%) — but two value-oriented managers added aggressively (Greenhaven +33.8%, Front Street +176.6%). This is consistent with a stock in a turnaround/deleveraging phase where value buyers are accumulating into weakness while some holders take profits or recycle capital. The dataset covers only 5 tracked filer rows — not an exhaustive 13F census (not available in provided documents).

5. Explicit Data Gaps

The following are not available in provided documents and cannot be analyzed: current BAX share price, valuation multiples, and technical levels; company-specific news from the past week (2026-09-11 → 2026-09-18); broader macro news; FRED macro indicators (CPI, core PCE, unemployment, fed funds rate, 10-year Treasury, yield curve); prediction-market probabilities (e.g., Fed rate cut, 2026 recession odds); Q3 2026 earnings date and guidance specifics; and any post-March 2026 changes in institutional ownership.

6. Actionable Takeaways for Traders

1. Contrarian setup flagged by quant flow: MFI of 15.99 with a BUY signal (strength 0.7468) as of the 2026-09-17 session suggests recent selling pressure is statistically stretched. Traders who act on money-flow signals have a documented, fresh (yesterday's session) trigger — but should confirm with live price/volume data, which is not available in provided documents.
2. Fundamental floor is improving: The last confirmed fundamental datapoint (Q2 2026) showed broad-based 5% organic growth and a raised FY26 outlook — a supportive medium-term backdrop that reduces the risk that the oversold reading reflects deteriorating fundamentals (as opposed to sentiment/flow noise or macro pressure).
3. Discount the one-off: The tariff-refund boost to Q2 means the guidance raise is partially low-quality. Position sizing should reflect the possibility that H2 growth optically decelerates as that benefit lapses.
4. Value-buyer sponsorship: Aggressive additions by Greenhaven (+33.8%) and Front Street (+176.6%) against modest trimming by the largest holder provide a value-community floor narrative — with the major caveat that this evidence is ~6 months stale.
5. Watch leverage and the tariff line: Net-leverage-target commitment (10-K) plus tariff sensitivity (Q2 refund) are the two structural themes most likely to drive guidance revisions and re-ratings. Any future filing or release touching either is a re-rating catalyst.
6. Event risk: The next earnings catalyst date is not available in provided documents.

7. Key Points Summary Table

Bottom line: The documented picture for BAX is a medtech turnaround with confirmed broad-based top-line growth and a raised FY26 outlook, a fresh quant BUY signal on oversold money flow (as of 2026-09-17), and value-manager accumulation — offset by a partially one-off earnings beat, an active leverage-reduction program, and major gaps in current market and macro data. Any live trade should be validated against current price, news, and macro inputs once external data access is restored.

BAX — Fundamental Research Report

Company: Baxter International Inc (NYSE: BAX) Sector / Industry: Health Care / Health Care Equipment (per QuantOrb snapshot) Analysis date: 2026-09-18 Data note: All four data tools (get_fundamentals, get_balance_sheet, get_cashflow, get_income_statement) were queried in parallel and returned NO_DATA_AVAILABLE — external market data tools are disabled in this deployment. This report therefore reasons exclusively from the four source documents provided (QuantOrb money-flow snapshot, FY2025 10-K excerpt, Q2 2026 8-K press release, and the 13F-HR holdings snapshot). Any item not covered by these is flagged as "not available in provided documents."

1. Executive Summary

Baxter International is a global medtech company whose most recent reported quarter (Q2 2026, per the 8-K filed 2026-07-30) showed broad-based growth: sales of $2.96 billion, up 5% on both a reported and organic basis, with growth in all segments and divisions, GAAP diluted EPS of $0.26, adjusted diluted EPS of $0.56, and a raised full-year 2026 outlook. Management commentary emphasizes stabilization, balance-sheet strengthening, and continuous improvement under the "Baxter Growth and Performance System (GPS)" program.

Against this fundamental backdrop, the QuantOrb money-flow engine (2026-09-17 US session) shows an MFI reading of 15.99 with a BUY signal (strength 0.7468) — a quantitative screen output, explicitly not a recommendation. Institutional 13F data (as of 2026-03-31) shows a mixed but value-oriented holder base: deep-value manager Greenhaven Associates added 33.8% to its stake while largest holder Pzena trimmed 7.9%.

The key tension for traders: the quantitative signal and operating momentum are constructive, but the GAAP-to-adjusted EPS gap and a one-time tariff refund embedded in the Q2 beat warrant scrutiny, and the balance-sheet picture cannot be verified from the provided documents.

2. Company Profile

• Name / Ticker: Baxter International Inc (NYSE:BAX), per the 8-K press release header.
• Sector / Industry: Health Care / Health Care Equipment (per the QuantOrb money-flow engine snapshot).
• Self-description: "a global medtech leader" (CEO statement, Q2 2026 press release).
• Headquarters location reference: Deerfield, Ill. (press release dateline).
• Leadership: Andrew Hider is identified as president and CEO in the July 30, 2026 press release.
• Strategic framework: Management operates under the Baxter Growth and Performance System (GPS), focused on "further stabilizing the business, strengthening the balance sheet and driving a culture of continuous improvement" (8-K CEO quote).
• Portfolio note: The organic-growth definition in the 8-K references a Kidney Care Manufacturing and Supply agreement (Kidney Care MSA) whose impact is excluded from organic growth and is "not reflected in reportable segments" — indicating a manufacturing/supply arrangement exists outside the reportable segments. Further detail on this arrangement is not available in provided documents.
• Manufacturing footprint detail from the 10-K: Baxter operates the North Cove facility in Marion, N.C., a significant site discussed as a results factor (see Section 6).

3. Quantitative Money-Flow Signal (Most Recent Data Point: 2026-09-17)

This is the only document in the analysis window covering the past week (roughly 2026-09-11 → 2026-09-18):

Interpretation (with caveats): The Money Flow Index is an oscillator; a reading of 15.99 sits in the range conventionally associated with oversold conditions (below 20). Combined with the engine's BUY flag and strength of 0.7468, the screen suggests depressed money flow that the model interprets as a contrarian buy setup. Important caveats stated in the source itself: (a) this is "a quantitative screen output, not a recommendation"; (b) no price, volume, or chart data accompanies the snapshot, so the equity's price level, trend, and volatility are not available in provided documents. Traders should treat the screen as a timing/conditioning input, not a standalone thesis.

4. Most Recent Reported Fundamentals — Q2 2026 (8-K Item 2.02, filed 2026-07-30)

This is a press release furnished under Item 2.02, not an earnings call transcript — no Q&A, guidance mechanics, or management call commentary are available beyond the quoted statement.

Headline results: - Sales: $2.96 billion, +5% reported and +5% organic — "reflecting growth in all segments and divisions." - GAAP diluted EPS: $0.26 - Adjusted diluted EPS: $0.56 - Guidance action: Company raised full-year 2026 financial outlook (specific guidance figures are not available in provided documents).

Quality-of-beat considerations (derived strictly from the press release): 1. One-time tailwind: CEO Andrew Hider stated results "exceeded expectations on both the top and bottom lines, driven by both operating performance and an additional benefit from a tariff refund that was not previously contemplated in our guidance." The beat therefore contains a non-recurring component; the size of the tariff refund is not available in provided documents. 2. GAAP vs. adjusted gap: Adjusted EPS ($0.56) is more than double GAAP EPS ($0.26), implying substantial non-GAAP adjustments (reconciliations are referenced in the release but their contents are not available in provided documents). Traders should not annualize the adjusted figure without understanding the adjustments. 3. Organic definition: Organic growth excludes (a) the Kidney Care MSA impact not reflected in reportable segments, (b) acquisition/divestiture impacts, and (c) is calculated at constant currency. Reported and organic growth being equal at +5% suggests no large M&A/divestiture or FX distortion in the quarter, per the definitions given.

Management posture: CEO language balances encouragement ("steady progress and core operating momentum") with caution ("we remain focused on the work ahead"), and reiterates balance-sheet strengthening as a GPS priority — implying management itself views the balance sheet as an ongoing work item (actual leverage metrics are not available in provided documents).

5. FY2025 Financial Data Points (10-K, filed 2026-02-12)

The 10-K excerpt provides only selected figures — full FY2025 income statement, balance sheet, and cash-flow statement detail is not available in provided documents. What the excerpt does establish:

• Capital expenditures: $513 million in 2025, directed at "new and existing product capacity expansions," projects "structured to improve production efficiency, enhance our quality systems and optimize manufacturing capabilities to support our business growth."
• Dividends: Cash dividends paid to stockholders totaled $348 million in 2025 — an active shareholder-return program. Per-share dividend rate and yield are not available in provided documents.
• Capital allocation stance: The excerpt frames capital allocation as "designed to optimize stockholder value creation in a manner and timing consistent with our previously stated commitment to achieve our net leverage targets" — confirming deleveraging is an explicit, previously stated commitment.
• Interpretation: Capex ($513M) exceeded dividends ($348M) in FY2025, i.e., the company prioritized capacity/quality investment over distribution size; whether this was funded by operating cash flow is not available in provided documents (full cash-flow statement unavailable).

6. Operational History / Risk Factor — Hurricane Helene & North Cove

The 10-K lists Hurricane Helene as a "factor affecting results of operations":

• Event: September 2024 — significant rain and extensive flooding in Western North Carolina caused damage to certain assets at the North Cove facility in Marion, N.C. and disrupted operations at that facility.
• Resolution: The facility was fully operational by the end of Q1 2025.
• Trader relevance: The disruption is a FY2024/early-FY2025 comparison-base issue; by Q2 2026 it should be fully lapped, meaning the +5% Q2 2026 organic growth was achieved without a hurricane-recovery tailwind — a modest quality positive for the reported growth rate. Any lingering insurance recoveries or remediation costs related to North Cove are not available in provided documents.

7. Institutional Ownership (13F-HR, positions as of 2026-03-31)

Per the quantorb filers dataset — 5 institutional filer rows on file; this is the tracked top-holder snapshot, not an exhaustive list of 13F filers, and it is subject to the statutory reporting lag of up to 45 days. It is nearly six months stale relative to today's date.

Read-through: - Concentration: Pzena is by far the largest tracked holder (64.5M shares — roughly 4x the next holder), so its −7.9% trim is the largest absolute share reduction (~5.5M shares) but modest relative to its position. - Value-manager bifurcation: Both Pzena (deep-value) and Greenhaven (value) are known value-oriented shops; one trimmed, one added aggressively (+33.8%). Front Street's +176.6% add from a small base signals accumulating interest among smaller holders. - Net signal: Mixed — two adds, two trims, one new — consistent with a stock in transition rather than a one-way institutional trend. Aggregate holdings, total institutional ownership percentage, and any Q2 2026 (June 30) or later ownership changes are not available in provided documents.

8. Data Gaps — Not Available in Provided Documents

For completeness, the following items a trader would normally want are not available in provided documents:

• Current share price, market capitalization, valuation multiples (P/E, EV/EBITDA, P/S), and 52-week range
• Full income statement (FY2025 revenue, gross/operating margins, net income; Q2 2026 segment revenue, margins, net income)
• Full balance sheet (cash, gross/net debt, leverage ratios — even though "net leverage targets" are referenced)
• Full cash-flow statement (operating cash flow, free cash flow — only capex of $513M and dividends of $348M for FY2025 are disclosed)
• FY2026 guidance specifics (the outlook was "raised," but figures are not included in the excerpt)
• Size of the tariff refund benefit in Q2 2026
• Per-share dividend rate and dividend yield
• Earnings call commentary (the 8-K is expressly not a transcript)
• Any company-specific news, filings, or events between 2026-08-01 and 2026-09-17; the only past-week data point is the 2026-09-17 QuantOrb snapshot
• Total institutional ownership and 13F snapshots after 2026-03-31

9. Actionable Insights for Traders

1. Contrarian quantitative setup, unconfirmed by price data: MFI of 15.99 with BUY (strength 0.7468) on 2026-09-17 suggests oversold money-flow conditions. If acting on the screen, size positions for a mean-reversion trade and verify with price/volume data, which are not available in provided documents.
2. Operating momentum is real but flattered: Q2 2026 delivered +5% reported and organic growth across all segments — broad-based, not one-division-driven — and management raised FY2026 guidance. However, the beat explicitly included an un-guided tariff refund benefit. Treat the underlying run-rate as below the headline beat until the refund's size is known (not available in provided documents).
3. Mind the GAAP/adjusted gap: $0.26 GAAP vs. $0.56 adjusted EPS means over half the adjusted figure rests on non-GAAP adjustments. Screen-based or yield-based models anchored to adjusted EPS carry estimation risk.
4. Deleveraging is the stated priority — monitor it: Both the 10-K (commitment to "net leverage targets") and the Q2 CEO quote ("strengthening the balance sheet") flag leverage as an open work item. Deleveraging can cap buybacks/M&A and compress multiples if progress stalls; the actual leverage ratio is not available in provided documents and should be pulled before position sizing.
5. Income support exists: $348M of dividends paid in FY2025 confirms a continuing dividend; a stable/raised dividend alongside deleveraging would support the total-return case. Per-share rate/yield: not available in provided documents.
6. Supply-chain risk largely reset: North Cove (Hurricane Helene) was fully operational by end-Q1 2025, so the FY2024/25 disruption is behind the company; Q2 2026 growth is a clean comparison. Note the 10-K's emphasis on capex toward capacity and quality systems — consistent with a company de-risking manufacturing.
7. Institutional tape is split, not bearish: Greenhaven +33.8% and Front Street +176.6% adds vs. Pzena −7.9% and Pale Fire −23.7% trims. Watch the Q2 2026 13F cycle (filed up to 45 days after 2026-06-30) for confirmation — that data is not available in provided documents.
8. Timeliness caveat: The most recent fundamental filing in the provided set is dated 2026-07-30 (Q2 8-K). Nearly seven weeks have passed; any interim developments (including Q3 pre-announcements or the next 10-Q) are not available in provided documents.

Bottom line: The documented fundamental picture — broad-based +5% growth, raised guidance, ongoing dividends, and disciplined capex — is constructive, and the 2026-09-17 money-flow screen adds an oversold contrarian signal. The posture best supported by the evidence is a cautiously constructive / accumulation-on-confirmation stance, contingent on (a) verifying price/volume and leverage data not present here, and (b) discounting the one-time tariff-refund component of the Q2 beat.

10. Key Points Summary Table

Report prepared 2026-09-18. All evidence limited to the four source documents cited above; tools get_fundamentals, get_balance_sheet, get_cashflow, and get_income_statement returned NO_DATA_AVAILABLE in this deployment.